Cargando…

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Detalles Bibliográficos
Autores principales:	Wang, Xi, Cao, Ruiyuan, Zhang, Huanyu, Liu, Jia, Xu, Mingyue, Hu, Hengrui, Li, Yufeng, Zhao, Lei, Li, Wei, Sun, Xiulian, Yang, Xinglou, Shi, Zhengli, Deng, Fei, Hu, Zhihong, Zhong, Wu, Wang, Manli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195821/ https://www.ncbi.nlm.nih.gov/pubmed/32373347 http://dx.doi.org/10.1038/s41421-020-0169-8

Ejemplares similares

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
por: Liu, Jia, et al.
Publicado: (2020)

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
por: Wang, Manli, et al.
Publicado: (2020)

Infection of human sweat glands by SARS-CoV-2
por: Liu, Jia, et al.
Publicado: (2020)

Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats
por: HU, Yunzhen, et al.
Publicado: (2021)

SARS-CoV-2 cell tropism and multiorgan infection
por: Liu, Jia, et al.
Publicado: (2021)

Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China
por: Guo, Yong-zheng, et al.
Publicado: (2020)

Antiviral effects and tissue exposure of tetrandrine against SARS‐CoV‐2 infection and COVID‐19
por: Liu, Jia, et al.
Publicado: (2023)

Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro
por: Zhang, Leike, et al.
Publicado: (2020)

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals
por: Yang, Chunguang, et al.
Publicado: (2020)

Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
por: Liu, Lei, et al.
Publicado: (2021)

Successful Rescue of Synthetic AcMNPV with a ~17 kb Deletion in the C1 Region of the Genome
por: Guo, Yijia, et al.
Publicado: (2022)

Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection In Vitro
por: Wang, Xi, et al.
Publicado: (2023)

Hemagglutinin Stability Determines Influenza A Virus Susceptibility to a Broad-Spectrum Fusion Inhibitor Arbidol
por: Li, Zhenyu, et al.
Publicado: (2022)

Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo
por: Wang, Qianran, et al.
Publicado: (2022)

Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases
por: Bai, Xinfeng, et al.
Publicado: (2023)

A trial of arbidol hydrochloride in adults with COVID-19
por: Zhao, Jingya, et al.
Publicado: (2022)

Efficacy of arbidol in COVID-19 patients: A retrospective study
por: Wei, Shuo, et al.
Publicado: (2021)

The Antiviral Drug Arbidol Inhibits Zika Virus
por: Fink, Susan L., et al.
Publicado: (2018)

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo
por: Zhong, Qiong, et al.
Publicado: (2009)

Arbidol as a broad-spectrum antiviral: An update
por: Blaising, Julie, et al.
Publicado: (2014)

Arbidol: The current demand, strategies, and antiviral mechanisms
por: Kang, Yue, et al.
Publicado: (2023)

Real-world experience of arbidol for Omicron variant of SARS-CoV-2
por: Zhao, Jingya, et al.
Publicado: (2023)

Glycomic Analysis Reveals That Sialyltransferase Inhibition Is Involved in the Antiviral Effects of Arbidol
por: Kang, Yue, et al.
Publicado: (2022)

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
por: Li, Hailong, et al.
Publicado: (2021)

Beneficial effect of Arbidol in the management of COVID-19 infection
por: Jie, Xiong, et al.
Publicado: (2021)

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
por: Li, Yueping, et al.
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Synthesis and biological activity of water-soluble polymer complexes of arbidol
por: Eropkin, M. Yu., et al.
Publicado: (2010)

A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019
por: Wang, Xuemei, et al.
Publicado: (2020)

“Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy
por: Deng, Hongsheng, et al.
Publicado: (2023)

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)

A commentary on ‘Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection’
por: Xu, Ruiyuan, et al.
Publicado: (2023)

Mechanism of Inhibition of Enveloped Virus Membrane Fusion by the Antiviral Drug Arbidol
por: Teissier, Elodie, et al.
Publicado: (2011)

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
por: Nojomi, Marzieh, et al.
Publicado: (2020)

Conformational Screening of Arbidol Solvates: Investigation via 2D NOESY
por: Eventova, Varvara A., et al.
Publicado: (2023)

Construction and Characterization of Severe Fever with Thrombocytopenia Syndrome Virus with a Fluorescent Reporter for Antiviral Drug Screening
por: Wang, Xiao, et al.
Publicado: (2023)

Combination of IMOD™ and Arbidol to increase their immunomodulatory effects as a novel medicine to prevent and cure influenza and some other infectious diseases
por: Arastoo, Mahmoud, et al.
Publicado: (2014)

Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission: A Preliminary Report of a Retrospective Cohort Study
por: Zhang, Jin-nong, et al.
Publicado: (2020)

Ficolin A exacerbates severe H1N1 influenza virus infection-induced acute lung immunopathological injury via excessive complement activation
por: Wu, Xu, et al.
Publicado: (2021)

Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study
por: Zhou, Xianlong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3v915kp0eako6l1k771rnqa3h1